Overview
This study aims to observe and explore the efficacy and safety of selinexor-based regimen in patients with Non-Hodgkin lymphoma
Description
this study aims to observe and explore the efficacy and safety of selinexor-based regimen in patients with DLBCL or T cell lymphoma. This study is a non-interventional real world, observational study and all registered data are collected from real clinical practice cases. The medical data includes patient demographic, tumor characteristics, laboratory examination, history of treatments, adverse reactions, efficacy results and possible prognostic factors.
Eligibility
Inclusion Criteria:
- Know and voluntarily sign the Informed Consent Form (ICF)
- Clinically confirmed DLBCL, T or NK cell lymphoma
- Patients with DLBCL or T or NK cell lymphoma who have used selinexor-based therapy in the past 3 months are included
- Cooperate with clinical diagnosis and treatment management, and provide disease-related past medical history materials
Exclusion Criteria:
- Previously received selinexor
- Poor patient compliance
- physicians evaluate that patients are not suitable for enrollment
